Cybin publishes FY2026 annual report

• Cybin published its annual report for the year ended March 31, 2026, highlighting continued focus on developing novel serotonergic agonists.
• Operations were presented in U.S. dollars following a presentation-currency change effective April 1, 2025, to align reporting with its cost base.
• The company began operating under the registered business name Helus Pharma on Jan. 5, 2026.
• Share-related figures were restated to reflect a 1-for-38 common-share consolidation completed on Sept. 19, 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.